[go: up one dir, main page]

GB916778A - Oral compositions containing 3-substituted 17-ª--methyl testosterones - Google Patents

Oral compositions containing 3-substituted 17-ª--methyl testosterones

Info

Publication number
GB916778A
GB916778A GB34990/59A GB3499059A GB916778A GB 916778 A GB916778 A GB 916778A GB 34990/59 A GB34990/59 A GB 34990/59A GB 3499059 A GB3499059 A GB 3499059A GB 916778 A GB916778 A GB 916778A
Authority
GB
United Kingdom
Prior art keywords
methyl
tertosterone
enol
ethyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB34990/59A
Inventor
Alberto Ercoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Francesco Vismara SpA
Original Assignee
Francesco Vismara SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Francesco Vismara SpA filed Critical Francesco Vismara SpA
Priority to GB34990/59A priority Critical patent/GB916778A/en
Priority to BE590424A priority patent/BE590424A/en
Priority to CH504460A priority patent/CH389595A/en
Priority to AT334760A priority patent/AT243446B/en
Priority to FR837301A priority patent/FR568M/fr
Publication of GB916778A publication Critical patent/GB916778A/en
Priority to OA51016A priority patent/OA00921A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention comprises inter alia the 3-enol alkyl or cycloalkyl ethers of free or acylated 17a -methyl testosterone having from 4-8 carbon atoms in the alkyl or cycloalkyl group. The compounds are prepared by (a) reacting methyl magnesium bromide with the corresponding enol ether of androstene-3,17-dione or (b) reacting the appropriate alcohol with the 3-enol ethyl ether of 17a -methyl testerone free or acylated in the presence of an acid catalyst, e.g. p-toluene sulphonic acid. The above process (b) may be used to prepare other 3-enol alkyl and benzyl ethers of 17a -methyltestosterone especially those substituted with functional substituents such as nitro and halo substituents. 3-Alkylene ketals of 17a -methyltestosterone are prepared by reacting 3-alkylene ketals of D 4-androstene-3,17-dione with methyl magnesium halide.ALSO:An oral composition having a high androgenic and anobolic activity comprises a 3-enol ether or a 3-glycol ketal of 17a methyl tertosterone or a 17b ester thereof, mixed with an orally ingestible pharmaceutical carrier. The 3-enol ether of tertosterone has at the 3 position a residue of an aliphatic, alicyclic arylaliphatic, aromatic or heterocyclic alcohol. The residue may contain a straight or branch chain alkyl group, which may be substituted e.g. by halogen; an alkylene group e.g. ethylene, a tetrahydropyraryl group or maybe a sugar residue such as that of glucose, galactose or maltose. Preferred ethers have a straight alkyl chain of 4 to 8 carbon atoms with or without methyl or ethyl substituents, at the 3 position. Preferred glycol ketals are alkylene glycol ketals having 2 to 4 carbon atoms in the glycol group. The compositions may be in the form of coated or uncoated tablets, powders, syrups and capsules e.g. keratin or gelatin capsules and are stabilised by adding an alkaline oxide e.g. MgO or an alkaline carbonate. The preferred carrier is a lipid from animal or vegetable sources, specified lipid carriers are (a) oils e.g. coconut, corn, cottonseed, lard, linseed, olive, sunflower seed, palm, peanut, sesame, soya bean, wheat germ and egg yolk oil. (b) Fats e.g. butter fat, lard, cocoa butter or margarine fat; (c) esters of glycerol with high molecular weight long chain fatty acids of 10-22 C atoms; (d) the free fatty acids contained in fats or oils having 10 to 22 carbon atoms e.g. decenoic, decosanoic lauric, palmitic, stearic, archidic, oleic, linoleic and linolenic acids. Other adjuvants specified are magnesium stearate, talc, lactose, rice starch. The compositions may also contain androgenic and/or anabolic steroid hormones, antiseptics, antioxidants e.g. propyl gallate and/or preservatives. The active ingredient is present in an amount ranging from 0.1 to 7% by weight of the final composition. Specified active ingredients are the 3-sec.-butyl, 3-n-amyl -, 3 isoamyl -, 3 hexyl -, 3 - (2 - methyl) pentyl -, 3 - n - heptyl -, 3 cyclohexyl -, 3 benzyl -, 3 - isobutyl -, 3 - sec - (3,3 - dimethyl)-butyl -, 3 - (2 - ethyl) - butyl, 3 - octyl, 3-chloroethyl, 3 - n - butyl and 3 ethyl enol ether of 17a methyl tertosterone, the 3-ethyl-enol ether of 17a methyl tertosterone acetate and the 3 glycol ketal of 17a methyl tertosterone.
GB34990/59A 1959-05-04 1959-10-15 Oral compositions containing 3-substituted 17-ª--methyl testosterones Expired GB916778A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GB34990/59A GB916778A (en) 1959-10-15 1959-10-15 Oral compositions containing 3-substituted 17-ª--methyl testosterones
BE590424A BE590424A (en) 1959-05-04 1960-05-03 Hormonal compositions.
CH504460A CH389595A (en) 1959-05-04 1960-05-03 Process for the preparation of enol ethers of 4-3-keto steroids
AT334760A AT243446B (en) 1959-05-04 1960-05-03 Process for the preparation of enol ethers of Δ <4> -3-keto steroids
FR837301A FR568M (en) 1959-05-04 1960-08-31
OA51016A OA00921A (en) 1959-10-15 1964-12-24 A process for the preparation of 2-enole ethers of 17α-methyl testosterone.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB34990/59A GB916778A (en) 1959-10-15 1959-10-15 Oral compositions containing 3-substituted 17-ª--methyl testosterones

Publications (1)

Publication Number Publication Date
GB916778A true GB916778A (en) 1963-01-30

Family

ID=10372503

Family Applications (1)

Application Number Title Priority Date Filing Date
GB34990/59A Expired GB916778A (en) 1959-05-04 1959-10-15 Oral compositions containing 3-substituted 17-ª--methyl testosterones

Country Status (2)

Country Link
GB (1) GB916778A (en)
OA (1) OA00921A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037201A3 (en) * 1995-05-16 1997-01-03 Arch Dev Corp METHODS AND COMPOSITIONS FOR INHIBITING 5α-REDUCTASE ACTIVITY
WO2000066612A1 (en) * 1999-05-04 2000-11-09 Strakan Limited Androgen glycosides and androgenic activity thereof
US8466138B2 (en) 2005-10-12 2013-06-18 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US9125816B2 (en) 2000-08-30 2015-09-08 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037201A3 (en) * 1995-05-16 1997-01-03 Arch Dev Corp METHODS AND COMPOSITIONS FOR INHIBITING 5α-REDUCTASE ACTIVITY
WO2000066612A1 (en) * 1999-05-04 2000-11-09 Strakan Limited Androgen glycosides and androgenic activity thereof
US6630453B1 (en) 1999-05-04 2003-10-07 Strakan Limited Androgen derivatives and uses thereof
US6916791B2 (en) 1999-05-04 2005-07-12 Strakan Limited Androgen derivatives and uses thereof
US9132089B2 (en) 2000-08-30 2015-09-15 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
US9125816B2 (en) 2000-08-30 2015-09-08 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
US8466137B2 (en) 2005-10-12 2013-06-18 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US8486925B2 (en) 2005-10-12 2013-07-16 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US8729057B2 (en) 2005-10-12 2014-05-20 Unimed Pharmaeuticals, LLC Testosterone gel and method of use
US8741881B2 (en) 2005-10-12 2014-06-03 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US8754070B2 (en) 2005-10-12 2014-06-17 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US8759329B2 (en) 2005-10-12 2014-06-24 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US8466136B2 (en) 2005-10-12 2013-06-18 Unimed Pharmaceuticals, Llc Testosterone gel and method of use
US8466138B2 (en) 2005-10-12 2013-06-18 Unimed Pharmaceuticals, Llc Testosterone gel and method of use

Also Published As

Publication number Publication date
OA00921A (en) 1968-03-22

Similar Documents

Publication Publication Date Title
US4147783A (en) Oral pharmaceutical preparation
EP0159739B1 (en) Steroids for use as immunomodulators
US4220599A (en) Oral pharmaceutical preparation having androgenic activity
US4098802A (en) Oral pharmaceutical preparation having androgenic activity
US4071623A (en) Pharmaceutical preparation adapted for oral administration
KR100666016B1 (en) Formulation comprising testosteron undecanoate and castor oil
US4083973A (en) Pharmaceutical preparation adapted for oral administration
WO2005076899A2 (en) Oral androgen therapy using modulators of testosterone bioavailablity
Schoonen et al. Steroid metabolism in the seminal vesicles of the African catfish, Clarias gariepinus (Burchell), during the spawning season, under natural conditions, and kept in ponds
GB916778A (en) Oral compositions containing 3-substituted 17-ª--methyl testosterones
Callow et al. The effect of the administration of testosterone propionate on the urinary excretion of compounds allied to the steroid hormones
EP0808845B1 (en) New 1- or 6-hydroxylated steroids, a process for their production, their use as medicaments and pharmaceutical compositions containing them
SU1277943A1 (en) Zootechnical composition
US3121042A (en) Oral compositions containing 3-enolethers of methyltestosterone
EP0001851B1 (en) Highly concentrated pharmaceutical formulations of steroids and processes for their preparation
JPS6145637B2 (en)
US5102912A (en) Hydroxyoctadecadienic acid for the treatment of estrogen-dependent disease
US3009858A (en) 3-(beta-haloethyl) enolether of cortisone acetate
Sim et al. Effect of dietary oil, cholesterol, and soysterols on the lipid concentration and fatty acid composition of egg yolk, liver and serum of laying hens
US20180333423A1 (en) Methods of treating testosterone deficiency
Barnes et al. Effects of the Prevention of Coprophagy in the Rat: V. Essential Fatty Acid Deficiency
US3342682A (en) Oral compositions containing 3-enol ethers of progesterone or 6-methyl derivatives thereof and method of using the same
US3240671A (en) Therapeutic composition containing the 3-cyclopentyl enol ether of 17alpha-acetoxy progesterone and method of using the same
GB931115A (en) Pharmaceutical preparations containing sitosterols
CA1083139A (en) Pharmaceutical preparation adapted for oral administration